Shots:
- The EC has approved Lojuxta (lomitapide capsules) for the treatment of children (≥5yrs.) with Homozygous Familial Hypercholesterolaemia (HoFH), alongside diet & other lipid-lowering treatments, incl. LDL-apheresis
- Approval was based on the P-III (APH-19) trial evaluating Lojuxta in 43 pediatric pts (5 to 17yrs.) with HoFH
- Trial met its 1EP, showing a mean 53.5% reduction in LDL‑C at Wk. 24, with significant reductions also achieved in non‑HDL‑C, total cholesterol, VLDL‑C, apolipoprotein B, and triglycerides
Ref: Globenewswire | Image: Chiesi | Press Release
Related News: Chiesi Group to Acquire KalVista Pharmaceuticals for ~$1.9B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
